Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2016 1
2017 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Bioactive Coatings Based on Nanostructured TiO2 Modified with Noble Metal Nanoparticles and Lysozyme for Ti Dental Implants.
Chifor E, Bordeianu I, Anastasescu C, Calderon-Moreno JM, Bratan V, Eftemie DI, Anastasescu M, Preda S, Plavan G, Pelinescu D, Ionescu R, Stoica I, Zaharescu M, Balint I. Chifor E, et al. Nanomaterials (Basel). 2022 Sep 14;12(18):3186. doi: 10.3390/nano12183186. Nanomaterials (Basel). 2022. PMID: 36144974 Free PMC article.
In order to modify their antibacterial activity, which is essential for safe dental implants, the following aspects were investigated: (a) singlet oxygen ((1)O(2)) generation by inorganic coatings exposed to visible light irradiation; (b) the antibacterial behavior emphasized by …
In order to modify their antibacterial activity, which is essential for safe dental implants, the following aspects were investigated: (a) s …
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).
McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, Agambaram V, Merideth C, Nordenhem A, Young AH; EMBOLDEN II (Trial D1447C00134) Investigators. McElroy SL, et al. J Clin Psychiatry. 2010 Feb;71(2):163-74. doi: 10.4088/JCP.08m04942gre. Epub 2010 Jan 26. J Clin Psychiatry. 2010. PMID: 20122366 Clinical Trial.
METHOD: 740 patients (478 bipolar I, 262 bipolar II) with major depressive episodes (DSM-IV) were randomly assigned to quetiapine 300 mg/d (n = 245), quetiapine 600 mg/d (n = 247), paroxetine 20 mg/d (n = 122), or placebo (n = 126) for 8 …
METHOD: 740 patients (478 bipolar I, 262 bipolar II) with major depressive episodes (DSM-IV) were randomly assigned to quetiapine 300 mg/ …
Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants.
Mischoulon D, Hylek L, Yeung AS, Clain AJ, Baer L, Cusin C, Ionescu DF, Alpert JE, Soskin DP, Fava M. Mischoulon D, et al. J Affect Disord. 2017 Jan 15;208:6-14. doi: 10.1016/j.jad.2016.08.029. Epub 2016 Oct 1. J Affect Disord. 2017. PMID: 27736689 Clinical Trial.
METHODS: 12 adults (67% female, mean age = 4512) with recurrent DSM-IV major depressive disorder (MDD) on dopaminergic antidepressant regimens (stimulants, dopamine agonists, bupropion [300mg/day], aripiprazole [2.5mg/day], or sertraline [150mg/day]) were randomized to naltrexone …
METHODS: 12 adults (67% female, mean age = 4512) with recurrent DSM-IV major depressive disorder (MDD) on dopaminergic antidepressant regime …
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Georgescu EF, et al. World J Gastroenterol. 2009 Feb 28;15(8):942-54. doi: 10.3748/wjg.15.942. World J Gastroenterol. 2009. PMID: 19248193 Free PMC article. Clinical Trial.
Subjects were randomly assigned either to the valsartan (V) group (standard dose 80 mg o.d., n = 26), or to the telmisartan (T) group (standard dose 20 mg o.d., n = 28). ...
Subjects were randomly assigned either to the valsartan (V) group (standard dose 80 mg o.d., n = 26), or to the telmisartan (T …